Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

Resistance to the Ableson protein tyrosine (Abl) kinase inhibitor imatinib mesylate has become a critical issue for patients in advanced phases of chronic myelogenous leukemia. Imatinib-resistant tumor cells develop, in part, as a result of point mutations within the Abl kinase domain. As protein ki...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tseng, Ping-Hui, Lin, Ho-Pi, Zhu, Jiuxiang, Chen, Kuen-Feng, Hade, Erinn M., Young, Donn C., Byrd, John C., Grever, Michael, Johnson, Kara, Druker, Brian J., Chen, Ching-Shih
Formato: Artigo
Idioma:Inglês
Publicado em: © 2005 by The American Society of Hematology 2005
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895085/
https://ncbi.nlm.nih.gov/pubmed/15665113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2004-07-2967
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados